Advertisement

Search Results

Advertisement



Your search for ,aGe matches 8736 pages

Showing 6151 - 6200


breast cancer
supportive care

Telephone and In-Person Counseling for Weight Loss Effective in Women Treated for Breast Cancer

In the LEAN (Lifestyle, Exercise, and Nutrition) study reported in the Journal of Clinical Oncology, Harrigan et al found that telephone and in-person weight loss counseling was effective in reducing weight and C-reactive protein level in overweight or obese women treated for breast cancer. In the ...

lung cancer

Pembrolizumab Improves Survival vs Docetaxel in Previously Treated PD-L1–Positive Advanced NSCLC

As reported in The Lancet by Herbst et al, the phase II/III KEYNOTE-010 trial showed that pembrolizumab (Keytruda) significantly improved overall survival vs docetaxel in patients with previously treated programmed death ligand 1 (PD-L1)–positive advanced non–small cell lung cancer...

gynecologic cancers
gynecologic cancers
issues in oncology

Study Shows ACA Coverage Expansion Resulted in Increased Cervical Cancer Diagnosis at Early Stage in Young Women

In a study reported in a research letter in JAMA, Robbins et al found evidence that the Affordable Care Act Dependent Coverage Expansion (ACA-DCE) has resulted in increased diagnosis of cervical cancer at an early stage and increased use of fertility-sparing treatments in women aged 21 to 25 years. ...

lung cancer

Statistically Significant Decline in Lung Cancer Incidence and Death Rates among Women

More than a decade after lung cancer incidence and death rates began to decline in men, a statistically significant decrease in the rates are occurring among women. The Annual Report to the Nation on the Status of Cancer, 1975 to 2007, is the first to document these decreases, the report’s authors...

prostate cancer

Death Rates Significantly Reduced for Men Having Radical Prostatectomy vs Watchful Waiting

Estimated 15-year results from the Scandinavian Prostate Cancer Group Study (SPCG-4) show that men diagnosed with early prostate cancer and randomly assigned to radical prostatectomy continued to have significantly reduced rates of death from prostate cancer, death from any cause, and risk of...

Expert Point of View: More Evidence Links Vitamin D Deficiency to Breast Cancer

Julie R. Gralow, MD, Professor of Oncology at the University of Washington, Seattle, said the data reported by Rickles et al at the American Society of Breast Surgeons Annual Meeting support the Goodwin study presented at the 2008 ASCO Annual Meeeting.1 In that earlier Canadian cohort of 512 women, ...

breast cancer

More Evidence Links Vitamin D Deficiency to Breast Cancer

Patients with breast cancer and deficient levels of 25-hydroxy-vitamin D are more likely to have aggressive tumor profiles and unfavorable prognostic markers than women with optimal levels of vitamin D, according to research presented at the 12th Annual Meeting of the American Society of Breast...

SIDEBAR: Nonrandomized Analysis Viewed with Skepticism

The findings from Grumley et al contradict the results from randomized trials of lumpectomy vs lumpectomy and radiotherapy for ductal carcinoma in situ (DCIS) and highlight the potential pitfalls of retrospective analyses. The meta-analysis of the DCIS trials revealed a significant 54% reduction in ...

gynecologic cancers

Important Briefs from the ACOG 59th Annual Clinical Meeting

Several presentations at the 59th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG), held April 30–May 4 in Washington, DC, focused on cancers associated with the reproductive tract and issues important to women’s health. Four noteworthy studies presented at...

issues in oncology

2011 ASCO Annual Meeting: Genes May Predict Taxane-related Peripheral Neuropathy

The first identification of potential genetic biomarkers for taxane-induced peripheral neuropathy was reported at the 2011 ASCO Annual Meeting by researchers from Indiana University in Indianapolis.1 The presence of two single nucleotide polymorphisms (SNPs), or common genetic variations, residing...

survivorship

A Conversation with Brad Zebrack, PhD, MSW, MPH

Each year in the United States, approximately 70,000 people between the ages of 15 and 40 are diagnosed with cancer. And while getting a cancer diagnosis at any age can be devastating, for adolescents and young adults (AYAs) grappling with sexuality, body image, peer pressure, dating, marriage,...

survivorship

Experts Seek to Explain the Survival Gap in Adolescents and Young Adults with Cancer

While overall cancer survival rates continue to rise-there are nearly 12 million cancer survivors today, according to the latest figures from NCI-most of that improvement is among pediatric and older adult patients. For adolescent and young adult patients with cancer, defined by the NCI as those in ...

gynecologic cancers

2011 ASCO Annual Meeting: 3-Year Screening Interval Safe for Women with HPV-negative and Normal Pap Tests, Data Show

A large, “real-world” study has validated current recommendations from the American Congress of Obstetricians and Gynecologists (ACOG), American Cancer Society (ACS), and American Society for Colposcopy and Cervical Pathology (ASCCP) endorsing a 3-year cervical cancer screening interval for women...

lymphoma
survivorship

Survivorship Symposium 2016: Study Finds That Less Than Half of Survivors of Hodgkin Lymphoma Received All Recommended Follow-up Care

According to the American Cancer Society’s 2014 Cancer Facts & Figures, Hodgkin lymphoma is diagnosed in about 800 adolescents and young adults each year. And while standard treatments for the cancer, including chemotherapy and radiation, are very effective in improving survival,...

gynecologic cancers

Cancer Diagnosis Can Spark Worry over Numerous Health Concerns

The early discovery of my endometrial cancer is a prime example of the health rewards you can reap if you are lucky enough to have good medical care and a dogged physician. Long past menopause, I wasn’t experiencing any of the typical warning signs of the disease—vaginal bleeding or pelvic...

prostate cancer

Sunitinib/Prednisone Improves Progression-free Survival but not Overall Survival in Metastatic Castrate-resistant Prostate Cancer

According to M. Dror Michaelson, MD, PhD, second-line therapy with sunitinib (Sutent) and prednisone improves progression-free survival but not overall survival in men with metastatic castrate-resistant prostate cancer previously treated with docetaxel-based chemotherapy. Dr. Michaelson, of the...

lung cancer

Understanding Crizotinib, 1 Year after High-profile Presentation

The findings from a phase I study of crizotinib in non–small cell lung cancer (NSCLC) were presented in a Plenary Session at the 2010 ASCO Annual Meeting—an unusual event, since such early-phase data are not generally the topic of plenary sessions. The study showed that a majority of mostly...

cns cancers

Plenary Report: Busulfan/Melphalan Improves Survival in High-risk Neuroblastoma Patients, Phase III Study Results Show

Myeloablative therapy with a busulfan (Busulfex, Myleran)/melphalan combination (BuMel) was superior to a regimen of carboplatin/etoposide/melphalan (CEM) in pediatric patients with high-risk neuroblastoma, according to results of the large, phase III HR-NBL1/SIOPEN trial presented at the 2011 ASCO ...

lymphoma

Important Briefs: Lymphoma Research on Improved Chemotherapy, Biomarker Associations, and Stem Cell Transplant Approaches

The 11th International Conference on Malignant Lymphoma was held June 15–18 in Lugano, Switzerland. More than 3,000 hematologists, clinical oncologists, pathologists, and researchers attended the meeting, which was first convened in 1981. Topics of discussion included lymphoma staging in the new...

colorectal cancer

Smoking and Lack of Exercise Increase Risk of Some Cancers, but Moderate Alcohol Consumption Reduces Colon Cancer Risk

A substudy of the large prospective National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial revealed both expected and surprising findings related to the association between lifestyle factors (cigarette smoking, alcohol, and exercise) and cancer risk. As might be...

skin cancer

Novel Agents Improve Survival in Patients with Metastatic Melanoma

Novel treatments for metastatic melanoma dominated the buzz at the 2011 ASCO Annual Meeting and across the major news outlets, with reports that two agents with entirely different mechanisms of action could extend survival. The studies’ inclusion in the ASCO Plenary Session attested to the...

breast cancer

Stalked by Cancer: One Woman’s Story

Cancer has been stalking me all my life. My mother’s mother had died of breast cancer at a relatively young age. My mother was diagnosed with breast cancer in the early 1960s, when she was 35 and I was just 5 years old. Although she was told that she probably wouldn’t live more than 2 years, she...

SIDEBAR: Expect Questions from Your Patients

The study of concurrent HPV and Pap testing for cervical cancer was widely reported even before the recent ASCO Annual Meeting. In an interview with The ASCO Post, Barnett Kramer, MD, was asked how physicians can respond to questions about the study from patients. “You can tell a woman over the...

gynecologic cancers

Cervical Cancer Screening Study Should Reassure Physicians and Patients that a 3-Year Screening Interval Is Safe and Effective

Results of a large-scale cervical cancer screening study using concurrent human papillomavirus (HPV) and Pap testing should “reassure” women over 30 who test negative for HPV and have normal Pap tests that “it is extremely safe to go 3 years” before being tested again, Barnett S. Kramer, MD, MPH,...

prostate cancer

Cabozantinib Shows Encouraging Activity in Metastatic Castrate‑resistant Prostate Cancer

Cabozantinib, a dual inhibitor of MET kinase and the vascular endothelial growth factor (VEGF) receptor, exhibits high, early single-agent activity in men with metastatic castrate-resistant prostate cancer, according to Maha Hussain, MD, FACP, who presented these findings at the 2011 ASCO Annual...

pain management

First Fentanyl Nasal Spray Approved for Cancer Breakthrough Pain

The FDA has approved fentanyl nasal spray (Lazanda) for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. This marks the first FDA product approval for...

kidney cancer

Studies Explore Potential Benefits of Sunitinib before Nephrectomy in Metastatic Clear Cell Renal Cancer

The multitargeted tyrosine kinase inhibitor sunitinib (Sutent) is established as first-line therapy in metastatic clear cell renal cancer. Data supporting use of cytoreductive nephrectomy in metastatic clear cell renal cancer come from the pre–targeted therapy era, when less-effective immune...

lymphoma

Intergroup Study Evaluates Outcomes of Elderly vs Younger Patients Treated for Advanced Hodgkin Lymphoma

The 11th International Conference on Malignant Lymphoma was held June 15–18 in Lugano, Switzerland. Topics of discussion included lymphoma staging in the new millennium, lymphoma and its microenvironment, and lymphoma cure vs control. The ASCO Post summarized several key presentations in the July...

breast cancer

Breast Cancer Studies Focus on Tailoring Therapy for Patient Subsets

As part of our ongoing coverage of the 2011 ASCO Annual Meeting, The ASCO Post has provided substantive reports on key breast cancer trials, but others deserve attention. Lapatinib/Capecitabine Controls Brain Metastases Results of the French phase II LANDSCAPE trial found lapatinib (Tykerb) plus...

lung cancer

Maintenance Therapy Prolongs Progression-free Survival in Advanced NSCLC but Produces No Overall Survival Benefit

Maintenance therapy with either pemetrexed (Alimta) or gefitinib (Iressa) achieved modest improvements in progression-free survival in patients with advanced non–small cell lung cancer (NSCLC). The magnitude of improved progression-free survival was 1.3 months and 2.2 months, respectively, in the...

health-care policy

Conflicts of Interest in Health-care Reform?

Last year’s health-care reform legislation, the Patient Protection and Affordable Care Act, was designed to incrementally roll out major new bureaucratic entities, oversight, and mandates for the practice of medicine between its enactment and 2013, after the next presidential election. A new...

breast cancer

Exemestane Prevents Invasive and Preinvasive Breast Cancers in MAP.3 Trial

The aromatase inhibitor exemestane, taken for 5 years, significantly reduced invasive and preinvasive breast cancers in postmenopausal women at increased risk for the disease, in the large Canadian NCIC CTG MAP.3 randomized trial. Results of the trial were presented at the recent ASCO Annual...

breast cancer

Higher Risk of Recurrence for Triple-negative Breast Cancer after Modified Radical Mastectomy without Radiation

“The paucity of therapeutic options” for women with triple-negative breast cancer “emphasizes the urgent need to optimize the current locoregional management of patients with [triple-negative breast cancer] and reduce their risk of locoregional recurrence,” noted the authors of a Canadian study...

leukemia

Conventional Induction Chemotherapy Beneficial in Only a Subset of Older Adults with AML

Over the past several decades, progress in the treatment of acute myeloid leukemia (AML) in the older population (generally considered to be older than 60 years) has been limited (Fig. 1). In particular, the outcome of patients over age 70 has been poor, with few long-term survivors. Although AML...

leukemia

Despite Advances, Little Overall Improvement Seen in Treatment of Older Adults with AML

The outcome of treatment of older adults with acute myeloid leukemia (AML) remains unsatisfactory, although certainly not a totally futile exercise. Patients satisfying the entry criteria for cooperative group clinical trials can be expected to have complete remission rates of 50% to 55%, with...

leukemia

Point of View: Should Patients Over 70 Receive Aggressive Therapy for Acute Myeloid Leukemia?

Despite Advances, Little Overall Improvement Seen in Treatment of Older Adults with AMLBy Charles A. Schiffer, MD The outcome of treatment of older adults with acute myeloid leukemia (AML) remains unsatisfactory, although certainly not a totally futile exercise. Patients satisfying the entry...

lymphoma

Combined Therapy Produces Good Outcomes in Primary Testicular Diffuse Large B-cell Lymphoma

Final results of an international phase II trial of first-line treatment for primary testicular diffuse large B-cell lymphoma show that using a combined treatment strategy including chemotherapy and central nervous system and testicular prophlaxis “was associated with a good outcome.” The results...

supportive care

Evaluating Risk for Suicide in People Diagnosed or Living with Cancer

The challenges of life-threatening physical illness can sometimes lead to suicide. In fact, given the critical stressors that a person with cancer faces, we might expect suicide to be a more common reaction. Patients with cancer are at increased risk of completed suicide, though the prevalence of...

gynecologic cancers

Bevacizumab Makes Inroads against Ovarian Cancer

Bevacizumab (Avastin) administered with chemotherapy and continued after chemotherapy improves outcomes in ovarian cancer, according to two multicenter, randomized, double-blind phase III investigations presented at the 2011 ASCO Annual Meeting. The first study, ICON7, incorporated bevacizumab as...

multiple myeloma

Second Primary Malignancies Explored in Multiple Myeloma

Three randomized controlled trials presented at the 2010 Annual Meeting of the American Society of Hematology (ASH) suggested that treating multiple myeloma with lenalidomide (Revlimid) increased the risk of second primary malignancies; of particular concern is transformation to acute myeloid...

breast cancer

Acting on Fear

When I was first diagnosed with breast cancer in 1979 there was no global movement to raise awareness of the disease, there were no pink ribbon pins to show support, and there was no Internet with which to search for information. My doctor gave me the news on a Friday night, and the following...

lung cancer

A Landmark Lung Screening Trial: What Does It Mean for Clinicians and Their Patients?

The NCI-funded National Lung Screening Trial (NLST), published recently in The New England Journal of Medicine,1 was heralded as a landmark study in lung cancer detection. This study is the first comprehensive clinical trial to find that screening high-risk individuals with low-dose CT reduces lung ...

colorectal cancer

Surgical Site Infections after Colectomy More Likely in Obese Patients

Obese patients appear to have a significantly increased risk of developing a surgical site infection after segmental or total colectomy for colon cancer, diverticulitis, or inflammatory bowel disease, and the presence of infection increases the cost associated with the procedure, according to a...

SIDEBAR: Age at Diagnosis and Importance of Long-term Considerations

"Patients are willing to accept self-limited acute adverse effects associated with recovery” after brachytherapy and radical prostatectomy, according to the study authors. These effects “have been well documented for both modalities and are quite different. Late effects have been less well...

prostate cancer

At 5 Years, Brachytherapy Shows Quality-of-life Advantages over Radical Prostatectomy for Favorable-risk Prostate Cancer

Five years after treatment for favorable-risk prostate cancer, men who either chose or were randomly assigned to receive brachytherapy reported quality-of-life advantages in urinary and sexual domains and in patient satisfaction compared to men who received radical prostatectomy, according to a...

head and neck cancer

Circulating Tumor Cell Assay Shows Potential for Predicting Prognosis in Head and Neck Carcinoma

According to the NCI, an estimated 49,260 new cases of oral cavity, pharyngeal, and laryngeal cancers occurred in the United States in 2010, and approximately 11,480 deaths were attributed to these cases. It is estimated that 95% or more of these cases are squamous cell carcinomas. Currently, the...

kidney cancer

Adjuvant Immunotherapy Provides No Clinical Benefit in Patients with High‑risk Renal Cell Carcinoma

For renal cell carcinoma patients at high risk of relapse following nephrectomy, adjuvant therapy with the combination of interleukin-2 (Proleukin), interferon alfa, and fluorouracil (5-FU) provides no survival benefit over observation alone, according to a phase III trial conducted by the European ...

lung cancer

World Conference on Lung Cancer: Personalized Approaches to Treatment

The 14th World Conference on Lung Cancer hosted more than 7,000 attendees in Amsterdam recently, with the theme “Better Care through Personalized Medical Approaches.” The following are brief summaries of key data presented at the conference, with perspective provided by Roy S. Herbst, MD, PhD, of...

breast cancer

Comorbidities Can Be as Important as Stage in Predicting Breast Cancer Survival in Older Patients

Comorbidities can be as important as stage in predicting survival among older women with breast cancer, according to a study in the Journal of the National Cancer Institute. While previous studies have combined comorbidities into a summary measure or comorbidity index, the current study assessed...

thyroid cancer

Wide Variation in Use of Radioactive Iodine for Thyroid Cancer

The proportion of patients with well-differentiated thyroid cancer who received radioactive iodine following total thyroidectomy increased significantly since 1990, and there is wide variation in the use of adjuvant radioactive iodine, according to a study in the Journal of the American Medical...

Advertisement

Advertisement




Advertisement